If you have been reading about albumin binding and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-25. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Stability studies focus on deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation into higher-order species. The fatty acid side chain adds susceptibility to oxidative change and can promote self-association at high concentration. Lyophilised material is comparatively robust when kept cold and dry, while aqueous solutions require refrigeration and protection from light. Forced degradation experiments under heat, acid, base, and peroxide conditions establish the specificity of each analytical method. Which degradation route dominates under real storage conditions depends on the formulation and stays formulation-specific.
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Technetium, with atomic number Z = 43, is the lowest-numbered element in the periodic table for which all isotopes are radioactive. The second-lightest exclusively radioactive element, promethium, has atomic number 61. Atomic nuclei with an odd number of protons are less stable than those with even numbers, even when the total number of nucleons (protons + neutrons) is even, and odd numbered elements have fewer stable isotopes. The most stable radioactive isotopes are technetium-97 with a half-life of 4.21±0.16 million years and technetium-98 with 4.2±0.3 million years; current measurements of their half-lives give overlapping confidence intervals corresponding to one standard deviation and therefore do not allow a definite assignment of technetium's most stable isotope. The next most stable isotope is technetium-99, which has a half-life of 211,100 years. Thirty-four other radioisotopes have been characterized with mass numbers ranging from 86 to 122. Most of these have half-lives that are less than an hour, the exceptions being technetium-93 (2.75 hours), technetium-94 (4.88 hours), technetium-95 (19.26 hours), and technetium-96 (4.28 days). The primary decay mode for isotopes lighter than technetium-98 (98Tc) is electron capture, producing molybdenum (Z = 42). For technetium-98 and heavier isotopes, the primary mode is beta emission (the emission of an electron or positron), producing ruthenium (Z = 44), with the exception that technetium-98 and technetium-100 can decay both by beta emission and electron capture.
== Pharmacokinetics == The absolute bioavailability of lobeglitazone is about 95% in rat. In human, the mean steady state clearance (CLss/F) was 1.13 L/h across in 1 to 4 mg dose range. In the dose range, the mean half-life was 10.3 h. Urine excretion was negligible amount in elimination of lobeglitazone in rat and human. The plasma protein binding of the drug is over 99%. The average blood-to-plasma concentration ratio was 0.636. The unbound fraction of lobeglitazone in microsomal incubation medium was 0.479. Lobeglitazone was primarily distributed to the liver with tissue-to-plasma concentration ratio as 5.59, and less to heart, lung, and fat. The tissue to plasma concentration ratios were ranged from about 0.25 to 4.0 for major tissues, in rat. Among six major membrane transporters recommended by the United States Food and Drug Administration, lobeglitazone interacts with OATP1B1, OAT3, and MDR1. In vitro, lobeglitazone was a substrate of rodent OATP1B2. Lobeglitazone interacted with CYP1A2, 2C9 and 2C19. Distribution to liver of lobeglitazone was inhibited by atorvastatin, in rats.
== Absorption, metabolism and excretion == When found in foods, most pantothenic acid is in the form of CoA or bound to acyl carrier protein (ACP). For the intestinal cells to absorb this vitamin, it must be converted into free pantothenic acid. Within the lumen of the intestine, CoA and ACP are hydrolyzed into 4'-phosphopantetheine. The 4'-phosphopantetheine is then dephosphorylated into pantetheine. Pantetheinase, an intestinal enzyme, then hydrolyzes pantetheine into free pantothenic acid. Free pantothenic acid is absorbed into intestinal cells via a saturable, sodium-dependent active transport system. At high levels of intake, when this mechanism is saturated, some pantothenic acid may also be additionally absorbed via passive diffusion. As a whole, when intake increases 10-fold, absorption rate decreases to 10%. Pantothenic acid is excreted in urine. This occurs after its release from CoA. Urinary amounts are on the order of 2.6 mg/day, but decreased to negligible amounts when subjects in multi-week experimental situations were fed diets devoid of the vitamin. Mutation of pantothenate kinase (the first enzyme in the pathway converting pantothenic acid to CoA) is the cause of pantothenate kinase associated neurodegeneration (PKAN), a rare neurodegenerative disease.
Fossils of what are thought to be filamentous photosynthetic organisms have been dated at 3.4 billion years old. More recent studies also suggest that photosynthesis may have begun about 3.4 billion years ago, though the first direct evidence of photosynthesis comes from thylakoid membranes preserved in 1.75-billion-year-old cherts. Oxygenic photosynthesis is the main source of oxygen in the Earth's atmosphere, and its earliest appearance is sometimes referred to as the oxygen catastrophe. Geological evidence suggests that oxygenic photosynthesis, such as that in cyanobacteria, became important during the Paleoproterozoic era around two billion years ago. Modern photosynthesis in plants and most photosynthetic prokaryotes is oxygenic, using water as an electron donor, which is oxidized to molecular oxygen in the photosynthetic reaction center.
An embalmer is someone who has been trained and qualified in the art and science of sanitization, presentation, and preservation of the human deceased. The term mortician is far more generic; it may refer to someone who is a funeral director, an embalmer, or just a person who prepares the deceased, with or without the formal qualification of an embalmer. Thus while all embalmers are morticians, many morticians are not embalmers and the terms are not intrinsically synonymous. Embalming training commonly involves formal study in anatomy, thanatology, chemistry, and specific embalming theory (to widely varied levels depending on the region of the world one lives in) combined with practical instruction in a mortuary with a resultant formal qualification granted after the passing of a final practical examination and acceptance into a recognized society of professional embalmers. The roles of a funeral director and embalmer are different, depending on local customs and the licensing body of the region in which they both operate. A funeral director arranges for the final disposition of the deceased, and may or may not prepare the deceased (by embalming, preparing for viewing or other legal requirements). Legal requirements over who can practice vary geographically. Some regions or countries do not have specific requirements, while others have clear prohibitions. In the United States, the title of an embalmer is largely based on the state in which they are licensed.
Sources: en.wikipedia.org
=== Prehistory === The first Aleutian occupants are thought to have arrived following Beringian migrations. Where the mainland of Alaska is thought to have been occupied before 15,000 years before present, the Aleutians were likely first occupied approximately 9,000 before present with the earliest archaeological sites found dating to that period, there is a possibility of an earlier occupation as early as 14,000 years ago as melting glaciers exposed the western shorelines of the Alaska Peninsula. The migration of the early Unangax̂ across the island chain would take thousands of years, beginning with the eastern islands, sites on Unalaska have been found which date to 9000 years before present. In the central islands, sites on Adak Island begin appearing approximately 6000 years before present. The western islands were the last settled, with sites beginning to appear 2,500 years before present. Within longest archaeological record in the Eastern Aleutians; the archaeological periods noted by archeologists Knecht and Davis are broken into Anangula phase (9000-7000 BP), Late Anangula (7000-4000 BP), the Margaret Bay Phase (4000-3000 BP), Amaknak Phase (3000-1000 BP), and the Late Aleutian Phase (1000-200 BP). The final three phases have also been noted as the Aleutian tradition. People living in the Aleutian Islands developed rich culture intimately tied to marine resources.
== Function == The Gβγ complex is an essential element in the GPCR signaling cascade. It has two main states for which it performs different functions. When Gβγ is interacting with Gα it functions as a negative regulator. In the heterotrimer form, the Gβγ dimer increases the affinity of Gα for GDP, which causes the G protein to be in an inactive state. For the Gα subunit to become active, the nucleotide exchange must be induced by the GPCR. Studies have shown that it is the Gβγ dimer that demonstrates specificity for the appropriate receptor and that the Gγ subunit actually enhances the interaction of the Gα subunit with the GPCR. The GPCR is activated by an extracellular ligand and subsequently activates the G protein heterotrimer by causing a conformational change in the Gα subunit. This causes the replacement of GDP with GTP as well as the physical dissociation of the Gα and the Gβγ complex.
== See also == David Ludwig (physician), American endocrinologist who promotes low-carb diets Diabetic diet, a diet that often focuses on eating low GI foods Disposition index, a biomarker for how strongly a spike in GI creates a feedback loop in blood sugar regulating hormones Glycemic efficacy Low glycemic index diet, diets which restrict carbohydrates and reduce blood sugar as an effect Montignac diet, fad diet based on minimizing GI and GL Overall nutritional quality index Retrogradation (starch)
Conservatives offered Thorpe the Home Office if he would join a coalition government with Heath. Thorpe was personally in favour of it, but the party insisted it would only agree pending a clear government commitment to introducing proportional representation (PR) and a change of prime minister. The former was unacceptable to Heath's cabinet and the latter to Heath personally, so the talks collapsed. Instead, a minority Labour government was formed under Harold Wilson but with no formal support from Thorpe. In the October 1974 general election, the Liberals total vote slipped back slightly (and declined in each of the next three) and the Labour government won a wafer-thin majority. Thorpe was subsequently forced to resign after allegations that he attempted to have his homosexual lover murdered by a hitman. The party's new leader, David Steel, negotiated the Lib–Lab pact with Wilson's successor as prime minister, James Callaghan. According to this pact, the Liberals would support the government in crucial votes in exchange for some influence over policy. The agreement lasted from 1977 to 1978, but proved mostly fruitless, for two reasons: the Liberals' key demand of PR was rejected by most Labour MPs, whilst the contacts between Liberal spokespersons and Labour ministers often proved detrimental, such as between Treasury spokesperson John Pardoe and Chancellor of the Exchequer Denis Healey, who were mutually antagonistic.
=== Selenoproteins === Selenocysteine has a lower reduction potential than cysteine. These properties make it very suitable in proteins that are involved in antioxidant activity. Although it is found in the three domains of life, it is not universal in all organisms. Unlike other amino acids present in biological proteins, selenocysteine is not coded for directly in the genetic code. Instead, it is encoded in a special way by a UGA codon, which is normally the "opal" stop codon. Such a mechanism is called translational recoding and its efficiency depends on the selenoprotein being synthesized and on translation initiation factors. When cells are grown in the absence of selenium, translation of selenoproteins terminates at the UGA codon, resulting in a truncated, nonfunctional enzyme. The UGA codon is made to encode selenocysteine by the presence of a selenocysteine insertion sequence (SECIS) in the mRNA. The SECIS element is defined by characteristic nucleotide sequences and secondary structure base-pairing patterns. In bacteria, the SECIS element is typically located immediately following the UGA codon within the reading frame for the selenoprotein. In Archaea and in eukaryotes, the SECIS element is in the 3′ untranslated region (3′ UTR) of the mRNA and can direct multiple UGA codons to encode selenocysteine residues. As of 2021, 136 human proteins (in 37 families) are known to contain selenocysteine (selenoproteins).
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.